Investor Type | Firm |
Industries | BioTech • Pharmaceutical (& Medicine) |
Stages | Seed, Series A |
Investing | United States |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $1,000,000,000 |
The AMR Action Fund is a biotechnology investment fund focused on the development of treatments for patients suffering from life-threatening antimicrobial-resistant (AMR) infections. Recognizing the growing threat of AMR, the fund aims to enable breakthroughs in antimicrobials with the objective of bringing 2 to 4 novel antibiotics to the market by 2030. Their investment strategy is to not only provide capital, but also to build partnerships to create a sustainable innovation ecosystem. This approach ensures that new treatments can continue to evolve alongside AMR challenges. With assets under management of $1 billion, the AMR Action Fund has a defined investment range of $100,000 to $5,000,000, with a sweet spot for investments at $1,500,000. They particularly specialize in Seed and Series A funding stages, primarily targeting enterprises within the Biotech and Pharmaceutical industries. Additionally, the fund advocates for market reforms and policy solutions that will help change how society values lifesaving drugs, signaling a commitment to addressing both economic and scientific aspects of AMR. Through their efforts, the AMR Action Fund not only focuses on investment but also on the larger ecosystem involving access, appropriate use principles, and the connection between investors and innovators. This multi-faceted approach underlines the fund's dedication to combating the pervasive threat of AMR and fostering a healthcare environment in which novel antibiotics can flourish.